Irina Blumenstein
Irina Blumenstein is an expert in Gastroenterology at University Hospital Frankfurt (Germany). As of October 2026, ScienceLeadR ranks Irina Blumenstein in the top 1% of experts worldwide for Colitis, Inflammatory Bowel Diseases and Gastroenteritis. Irina Blumenstein has authored 153 publications, the most recent in 2026, and is an investigator in 23 clinical trials, 15 of them ongoing. SLR score: 976 (community average: 125). How the SLR is computed.
LeadR Profile
Gastroenterology
Subspecialties: Biochemistry - Public Health - Hepatology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2003 - 2026
Number : 153
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| New Diagnostic Criteria for Acute Severe Ulcerative Colitis in the Modern Treatment Era: A Modified Delphi Consensus by REFINED-ASUC. PMID 42486394 — colitis, blood, adrenal cortex hormones, endoscopy, diagnosis, therapeutics, outpatients, steroids, movement, colitis, ulcerative | Clin Gastroenterol Hepatol | 2026 | 2 |
| ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment. PMID 42413123 — colitis, inflammatory bowel diseases, therapeutics, colitis, ulcerative, small molecules | J Crohns Colitis | 2026 | 8 |
| ECCO Guidelines on Therapeutics in Ulcerative Colitis: Surgical Treatment. PMID 42381162 — colitis, appendectomy, inflammatory bowel diseases, therapeutics, colitis, ulcerative | J Crohns Colitis | 2026 | 3 |
| Improvement in Health-Related Quality of Life in Patients With Moderate to Severe Crohn's Disease Treated With Risankizumab Versus Ustekinumab in the Phase 3B SEQUENCE Study. PMID 42085631 — quality of life, ustekinumab, gastroenterology, crohn disease, signs and symptoms, therapeutics | Am J Gastroenterol | 2026 | 0 |
| Drug Persistence of Patients with Inflammatory Bowel Disease Under Biological Treatment in the Pre IL-23 Era in a Tertiary Referral Center in Germany. PMID 41464821 — tertiary care centers, interleukin-23, pharmaceutical preparations, inflammatory bowel diseases, therapeutics, biological therapy, colitis, ulcerative | J Clin Med | 2025 | 0 |
Clinical Studies 23
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Ongoing Clinical Trials
15 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Efficacy and Safety of JNJ 78934804 in Participants With Moderately to Severely Active Crohn s Disease 2026-525922-39-00 — safety, crohn disease | Phase 3 | Not yet recruiting | 2026 |
| Efficacy and Safety of JNJ 78934804 in Participants with Moderately to Severely Active Ulcerative Colitis 2026-525923-26-00 — colitis, safety, colitis, ulcerative | Phase 3 | Recruiting | 2026 |
| A Study to Assess the Efficacy Safety and what the body does to RO7837195 in Participants with Moderately to Severely Active Ulcerative Colitis 2025-520690-39-00 — colitis, safety, therapeutics, colitis, ulcerative, pharmacokinetics | Phase 2 | Not yet recruiting | 2025 |
| An Adaptive Dose Ranging Phase 2 Study of Eltrekibart Given Alone or in Combination with Mirikizumab for the Treatment of Adult Patients with Moderately to Severely Active Ulcerative Colitis 2023-507853-13-00 — colitis, therapeutics, colitis, ulcerative | Phase 2 | Active not recruiting | 2025 |
| A Continuation Study of TAK 279 in Adults With Ulcerative Colitis (UC) and Crohn s Disease (CD) 2024-518914-18-00 — colitis, safety, crohn disease, therapeutics, colitis, ulcerative | Phase 2 | Not yet recruiting | 2025 |
LeadR Networks
Main global connection map